{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:00Z","timestamp":1761895260719},"reference-count":6,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T00:00:00Z","timestamp":1302739200000},"content-version":"vor","delay-in-days":3147,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:p><jats:bold>Zusammenfassung. <\/jats:bold> Zygomykosen (Mucormykosen) sind seltene Erkrankungen bei immunsupprimierten Patienten meist infolge von zytostatischer Therapie h\u00e4matologischer Neoplasien. Klinik und Pathogenese \u00e4hneln weitgehend denen einer invasiven Aspergillose. In retrospektiven Studien wird eine hohe Mortalit\u00e4t von etwa 80% berichtet. Als weitere Risikofaktoren wurden bei Patienten mit anderen Grunderkrankungen eine Eisen\u00fcberladung, die Therapie mit Glucokortikosteroiden oder Chelatbildnern und eine diabetische Ketoazidose beschrieben. Ob diesen Faktoren eine zus\u00e4tzliche Bedeutung bei h\u00e4matologischen Patienten zukommt, ist wenig untersucht worden. In einer Fall\u2010Kontrollstudie wurde die H\u00e4ufigkeit verschiedener Risikofaktoren bei 13 Patienten mit Zygomykose und 13 Kontrollpatienten mit gleicher Grunderkrankung, gleicher Therapie ohne Zygomykose untersucht. Patienten mit Zygomykose waren l\u00e4nger neutropen (17 vs. 13 Tage) und lymphopen (23 vs 20 Tage). Sie hatten h\u00e4ufiger ein Rezidiv ihrer Grunderkrankung (7\/13 vs. 3\/13), wurden h\u00e4ufiger mit Kortikosteroiden behandelt (8\/13 vs. 4\/13). Ebenso fand sich h\u00e4ufiger eine kardiovaskul\u00e4re Grunderkrankung (6\/13 vs. 1\/13), ein Diabetes mellitus (6\/13 vs. 3\/13) und eine systemische Prophylaxe mit Itraconazol (9\/13 vs. 4\/13). Die Kenntnis von Risikofaktoren f\u00fcr eine Zygomykose sollte eine raschere Diagnose, eine konsequente Therapie mit hochdosiertem Amphotericin B und gegebenenfalls eine chirurgische Intervention erm\u00f6glichen und damit die Prognose dieser Infektion verbessern.<\/jats:p><jats:p><jats:bold>Summary. <\/jats:bold> Zygomycosis (mucormycosis) is a relatively uncommon infection in immunocompromised patients most often diagnosed in patients with haematological malignancies and neutropenia. Postmortem series demonstrate a high mortality rate up to 80%. Pulmonary involvement mimicking the more frequently diagnosed invasive aspergillosis is the typical clinical presentation. Other risk factors for the development of zygomycosis that have been described in other patient populations include diabetic ketoacidosis, iron overload, use of deferoxamine and steroids. If these factors are also associated with zygomycosis in patients with haematological malignancies has not been described. In a retrospective case\u2010control study including 13 patients with zygomycosis and 13 control patients with the same underlying diseases, without zygomycosis we determined the frequency of various risk factors. Patients with zygomycosis experienced a longer period of neutropenia (17 vs. 13 days) and lymphopenia (23 vs. 20 days). A relapse of their underlying disease was diagnosed more frequently in patients with zygomycosis (7\/13 vs. 3\/13) as were a diagnosis of diabetes mellitus (6\/13 vs. 3\/13) and a cardiovascular disease (6\/13 vs. 1\/13). The previous use of steroids was more frequent in patients with zygomycosis (8\/13 vs. 4\/13) as was a systemic antifungal prophylaxis with itraconazole (9\/13 vs. 4\/13). Knowledge of these risk factors may be of benefit in diagnosing and monitoring zygomycosis in patients with haematological malignancies.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2002.tb04542.x","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T10:02:18Z","timestamp":1302775338000},"page":"27-30","source":"Crossref","is-referenced-by-count":24,"title":["Risikofaktoren f\u00fcr invasive Zygomykosen bei Patienten mit h\u00e4matologischen Neoplasien"],"prefix":"10.1111","volume":"45","author":[{"given":"V.","family":"Rickerts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"B\u00f6hme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Just\u2010N\u00fcbling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S126"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.236"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3983214.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701885"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(94)90243-7"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/030098589603300207"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2002.tb04542.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2002.tb04542.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:41:36Z","timestamp":1700314896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2002.tb04542.x"}},"subtitle":["Risk factors for invasive zygomycosis in patients with hematological malignancies"],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":6,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1111\/j.1439-0507.2002.tb04542.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2002.tb04542.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}